Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H L Davis

Showing results (81-90 of 162) with videos related to

Pageof 17
Sort By:
Cancer|August 1, 1974
Five-drug therapy in advanced breast cancer: factors influencing toxicity and responseH L Davis, G Ramirez, R A Ellerby, et al.
Vaccine|March 4, 2000
CpG DNA induces stronger immune responses with less toxicity than other adjuvantsR D Weeratna, M J McCluskie, Y Xu, et al.
Cancer|October 1, 1974
Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and CIS-platinum (II) diaminedichloride (NSC 119875)R A Ellerby, H L Davis, F J Ansfield, et al.
Cancer|May 1, 1973
Tryptophan metabolism in breast cancer. Correlation with urinary steroid excretionH L Davis, R R Brown, J Leklem, et al.
Cancer|April 1, 1974
A clinical trial of megestrol acetate in advanced breast cancerF J Ansfield, H L Davis, R A Ellerby, et al.
Oncology|January 1, 1973
Hypercalcemia complicating breast cancer. Clinical features and managementH L Davis, A N Wiseley, G Ramirez, et al.
Cancer Chemotherapy Reports|April 1, 1971
Five-drug therapy for advanced breast cancer: a phase I studyF J Ansfield, G Ramirez, B C Korbitz, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|August 31, 2001
The use of CpG DNA as a mucosal vaccine adjuvantM J McCluskie, R D Weeratna, P J Payette, et al.
Vaccine|June 8, 2001
Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvantsM J McCluskie, R D Weeratna, J D Clements, et al.
Gene Therapy|September 26, 2001
Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanismsP J Payette, R D Weeratna, M J McCluskie, et al.
Pageof 17

Showing results (81-90 of 162) with videos related to

Sort By:
Pageof 17
Cancer|August 1, 1974
Five-drug therapy in advanced breast cancer: factors influencing toxicity and responseH L Davis, G Ramirez, R A Ellerby, et al.
Vaccine|March 4, 2000
CpG DNA induces stronger immune responses with less toxicity than other adjuvantsR D Weeratna, M J McCluskie, Y Xu, et al.
Cancer|October 1, 1974
Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and CIS-platinum (II) diaminedichloride (NSC 119875)R A Ellerby, H L Davis, F J Ansfield, et al.
Cancer|May 1, 1973
Tryptophan metabolism in breast cancer. Correlation with urinary steroid excretionH L Davis, R R Brown, J Leklem, et al.
Cancer|April 1, 1974
A clinical trial of megestrol acetate in advanced breast cancerF J Ansfield, H L Davis, R A Ellerby, et al.
Oncology|January 1, 1973
Hypercalcemia complicating breast cancer. Clinical features and managementH L Davis, A N Wiseley, G Ramirez, et al.
Cancer Chemotherapy Reports|April 1, 1971
Five-drug therapy for advanced breast cancer: a phase I studyF J Ansfield, G Ramirez, B C Korbitz, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|August 31, 2001
The use of CpG DNA as a mucosal vaccine adjuvantM J McCluskie, R D Weeratna, P J Payette, et al.
Vaccine|June 8, 2001
Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvantsM J McCluskie, R D Weeratna, J D Clements, et al.
Gene Therapy|September 26, 2001
Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanismsP J Payette, R D Weeratna, M J McCluskie, et al.
Pageof 17